Unlocking the power of tumor-activated small molecule
Brimstalt is developing novel therapies for cancer offering improved safety and efficacy profiles for better patient outcomes
About Us
Brimstalt Therapeutics is a portfolio company of Fannin Innovation based in Houston, Texas. We are committed to developing first-in-class anticancer prodrugs that offer a much-needed targeted therapeutic strategy across multiple oncology indications. Our lead compounds show minimal-to-no activity until enzymatic activation by specific tumor associated enzymes that enable its potent cytotoxic effect.
Our platform of prodrugs are positioned as molecular marker driven, cancer origin agnostic, therapeutic options for common cancers with large patient populations and high unmet medical needs - initially renal cell carcinoma and prostate cancer - with optionality to expand into other rare cancer types including sarcoma, mesotheliomas, and hepatocellular carcinomas.
These have the potential to establish new standards of care and help tens of millions around the world.
Innovation
We are developing first-in-class small molecule prodrugs that are next generations targeted chemotherapeutics for a variety of cancers.
We aim to leverage the overexpression of certain intracellular enzymes in cancer cells to activate non-toxic prodrugs into cytotoxic chemotherapeutic moieties.
Brimstalt has a clinical candidate small molecule drug that is activated by a specific tumor associated enzyme (TAE).
We are developing this drug as a highly selective therapy for patients diagnosed with cancers expressing the TAE (irrespective of tissue of origin) who have limited therapeutic options.
The drug has shown significant ability to reduce tumor burden in mouse models of cancer.